Protein Information

ID 2727
Name Pit 1
Synonyms GLVR 1; PIT1; Pit 1; GLVR1; Gibbon ape leukemia virus receptor 1; Leukemia virus receptor 1 homolog; Phosphate transporter 1; SLC20A1…

Compound Information

ID 1779
Name phosphorus
CAS phosphorus

Reference

PubMed Abstract RScore(About this table)
19675183 Giral H, Caldas Y, Sutherland E, Wilson P, Breusegem S, Barry N, Blaine J, Jiang T, Wang XX, Levi M: Regulation of rat intestinal Na-dependent phosphate transporters by dietary phosphate. Am J Physiol Renal Physiol. 2009 Nov;297(5):F1466-75. Epub 2009 Aug 12.
Hyperphosphatemia associated with chronic kidney disease is one of the factors that can promote vascular calcification, and intestinal P (i) absorption is one of the pharmacological targets that prevents it. The type II Na-P (i) cotransporter NaPi-2b is the major transporter that mediates P (i) reabsorption in the intestine. The potential role and regulation of other Na-P (i) transporters remain unknown. We have identified expression of the type III Na-P (i) cotransporter PiT-1 in the apical membrane of enterocytes. Na-P (i) transport activity and NaPi-2b and PiT-1 proteins are mostly expressed in the duodenum and jejunum of rat small intestine; their expression is negligible in the ileum. In response to a chronic low-P (i) diet, there is an adaptive response restricted to the jejunum, with increased brush border membrane (BBM) Na-P (i) transport activity and NaPi-2b, but not PiT-1, protein and mRNA abundance. However, in rats acutely switched from a low- to a high-P (i) diet, there is an increase in BBM Na-P (i) transport activity in the duodenum that is associated with an increase in BBM NaPi-2b protein abundance. Acute adaptive upregulation is restricted to the duodenum and induces an increase in serum P (i) that produces a transient postprandial hyperphosphatemia. Our study, therefore, indicates that Na-P (i) transport activity and NaPi-2b protein expression are differentially regulated in the duodenum vs. the jejunum and that postprandial upregulation of NaPi-2b could be a potential target for treatment of hyperphosphatemia.
2(0,0,0,2)